Rome, Italy 30 August 2016: New generation drug eluting stents (new DES) did not outshine contemporary bare metal stents (BMS) as they were expected to, in a surprise finding of the largest randomized stent trial to date.
The Norwegian Coronary Stent Trial (NorStent), presented at ESC Congress 2016, and published simultaneously in the New England Journal of Medicine, "demonstrates that the efficacy of new DES versus contemporary BMS is lower than expected," noted Kaare Harald Bonaa, MD, PhD, in a Hot Line session here.